Table 3.
RANKL and OPG Expression per Group of Pathologies Studied
| Group | Serum concentration (pg/ml) mean ± SD | mRNA expression (relative expression/18S) mean ± SD | ||||
|---|---|---|---|---|---|---|
| OPG | RANKL | RANKL/OPG | OPG | RANKL | RANKL/OPG | |
| Control | 236.5 ± 66.6 (n = 13) | 66.4 ± 86.9 (n = 13) | 0.32 ± 0.38 | 1.82 ± 2.00 (n = 14) | 0.45 ± 0.44 (n = 14) | 0.27 ± 0.23 |
| Total hip arthroplasty | 437.2 ± 306.9 (n = 16) | 198.1 ± 163 (n = 16) | 0.99 ± 1.50 | 1.47 ± 1.58 (n = 15) | 0.49 ± 0.4 (n = 15) | 0.51 ± 0.53 |
| Giant cell tumors | 207.2 ± 126.8 (n = 4) | 160 ± 138.5 (n = 4) | 1.13 ± 1.20 | 0.97 ± 0.49 (n = 6) | 0.54 ± 0.51 (n = 6) | 0.48 ± 0.44 |
| Osteitis | 285 ± 106.1 (n = 2) | 285 ± 91.9 (n = 2) | 1.13 ± 0.74 | 1.08 ± 1.11 (n = 2) | 0.72 ± 0.7 (n = 2) | 0.60 ± 0.47 |
| Primary benign bone tumors | 229.3 ± 152.2 (n = 12) | 263.3 ± 349.1 (n = 12) | 0.45 ± 0.44 | 2.16 ± 2.03 (n = 6) | 0.66 ± 0.43 (n = 6) | 0.48 ± 0.43 |
| Tumors of the soft tissues | 350 ± 264.6 (n = 3) | 396.6 ± 306.6 (n = 3) | 1.23 ± 1.50 | 0.26 (n = 1) | 0 (n = 1) | 0 |
| Hematologic malignancies | 505 ± 176.7 (n = 2) | 140 ± 198 (n = 2) | 0.22 ± 0.31 | ND | ND | NA |
| Primary malignant bone tumors | 299.1 ± 234.5 (n = 9) | 235.4 ± 272.3 (n = 9) | 1.05 ± 1.53* | 1.23 ± 1.02 (n = 8) | 0.75 ± 0.40 (n = 8) | 1.08 ± 1.29** |
| Bone metastasis from other primary origins | 319.6 ± 163.4 (n = 8) | 393.7 ± 267.2 (n = 8)* | 1.55 ± 1.54** | 0.66 ± 0.46 (n = 5) | 0.69 ± 0.54 (n = 5) | 1.92 ± 2.50** |
| Tumors associated with severe osteolysis | 318.8 ± 190.6 (n = 18) | 226.6 ± 243.5 (n = 18) | 1.04 ± 1.36* | 0.75 ± 0.50 (n = 9) | 0.57 ± 0.47 (n = 9) | 1.03 ± 1.58* |
*P < 0.05 and **P < 0.01 compared to the control group; ND, not determined; NA, non-applicable.